阿司匹林联合双嘧达莫预防老年非瓣膜性心房颤动血栓栓塞事件的临床研究

Clinical observation of combination aspirin and dipyridamole for prevention of thromboembolic events in aged patients with nonvalvular atrial fibrillation

目的观察阿司匹林联合双嘧达莫预防老年非瓣膜性心房颤动(房颤)患者发生血栓栓塞事件的有效性与安全性。方法将确诊的老年非瓣膜性房颤患者195例,随机分为2组。阿司匹林联合双嘧达莫组(联合治疗组)给予阿司匹林(100 mg,1次/d)+双嘧达莫(100 mg,3次/d);阿司匹林组给予(100 mg,1次/d)。观察2组血栓栓塞事件、出血及其他不良反应的发生率。结果随访时间12～28(20±7)个月。2组均无严重出血。联合治疗组血栓栓塞事件的发生率明显低于阿司匹林组(8.3%比18.2%,P<0.05),轻微出血及其他不良反应总的发生率差异无统计学意义(14.6%比8.1%,P>0.05)。结论阿司匹林联合双嘧达莫预防老年非瓣膜性房颤血栓栓塞事件安全有效。

Objective To observe the efficiency and safety of combination aspirin and dipyridamole for prevention of thromboembolism events in aged patients with nonvalvular atrial fibrillation. Methods Totally 195 aged nonvalvular atrial fibrillation patients were randomly divided into two groups, which aspirin and combined with dipyridamole treatment group received aspirin 100 mg Qd plus dipyridamole 100mg Tid, while aspirin treatment group received aspirin 100mg Qd only. The incidence of thromboembolism, hemorrhage and other adverse events were observed and compared between two groups. Results The follow-up time was 12 -28 （20 -7 ） months. During the period, there was no serious hemorrhage in both two groups. The incidence of thromboembolism in combination group was obviously lower than that in aspirin group（8.3% vs 18.2% , P 〈0.05）. Between the two groups, there was no significant difference in the total incidence of adverse events （ 14.6% vs 8.1% , P 〉 0. 05 ）. Conclusion It demonstrated that combination aspirin and dipyridamole may effective and safe to reduce the incidence of thromboembolism events in aged patients with nonvalvular atrial fibrillation.